Archives of the
Turkish Society of Cardiology
Review - General

Iron deficiency and anemia in heart failure

1.

Eskişehir Osmangazi Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Eskişehir

2.

Başkent Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, İstanbul

3.

Koç Üniversitesi Tıp Fakültesi, İç Hastalıkları Anabilim Dalı / Hematoloji Bilim Dalı, İstanbul

4.

Dr. Siyami Ersek Eğitim ve Araştırma hastanesi, Kardiyoloji Kliniği, İstanbul

5.

Ankara Türkiye Yüksek İhtisas Hastanesi, Kardiyoloji Kliniği, Ankara

6.

Koç Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, İstanbul

7.

Uludağ Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Bursa

8.

Kırıkkale Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Kırıkkale

9.

Cumhuriyet Üniversitesi Tıp Fakültesi, Kardiyoloji Anabilim Dalı, Sivas

Archives of the Turkish Society of Cardiology 2017; 45: Supplement 1-38
DOI: 10.5543/tkda.2017.79584
Read: 1204 Downloads: 342 Published: 01 July 2021

Heart failure is an important community health problem. Prevalence and incidence of heart failure have continued to rise over the years. Despite recent advances in heart failure therapy, prognosis is still poor, rehospitalization rate is very high, and quality of life is worse. Co-morbidities in heart failure have negative impact on clinical course of the disease, further impair prognosis, and add difficulties to treatment of clinical picture. Therefore, successful management of co-morbidities is strongly recommended in addition to conventional therapy for heart failure. One of the most common co-morbidities in heart failure is presence of iron deficiency and anemia. Current evidence suggests that iron deficiency and anemia are more prevalent in patients with heart failure and reduced ejection fraction, as well as those with heart failure and preserved ejection fraction. Moreover, iron deficiency and anemia are referred to as independent predictors for poor prognosis in heart failure. There is strong relationship between iron deficiency or anemia and severity of clinical status of heart failure. Over the last two decades, many clinical investigations have been conducted on clinical effectiveness of treatment of iron deficiency or anemia with oral iron, intravenous iron, and erythropoietin therapies. Studies with oral iron and erythropoietin therapies did not provide any clinical benefit and, in fact, these therapies have been shown to be associated with increase in adverse clinical outcomes. However, clinical trials in patients with iron deficiency in the presence or absence of anemia have demonstrated considerable clinical benefits of intravenous iron therapy, and based on these positive outcomes, iron deficiency has become target of therapy in management of heart failure. The present report assesses current approaches to iron deficiency and anemia in heart failure in light of recent evidence.

Files
TURKISH
ISSN 1016-5169 EISSN 1308-4488